An observational study in Unruptured Intracranial Aneurysms, Pituitary Neuroendocrine Tumor and Craniopharyngioma, sponsored by Cheng sen. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Cheng sen · Observational
The goal of this observational study is to learn about the treatment strategies for tumor in sellar region with unruptured intracranial aneurysms in the Chinese population. The main question it aims to answer is: For patients with tumor in sellar region combined with unruptured intracranial aneurysms, which condition should be treated first?
The goal of this observational study is to clarify the treatment strategies for tumor in sellar region with unruptured intracranial aneurysms in the Chinese population aged from 18 to 75. The main question it aims to answer is:
Participants are required to:
This is an observational study. It solely collects patients' pre-operative, intra-operative, and post-operative follow-up information and does not influence the patient's treatment process or clinical decision-making.
76 studies on the registry are indexed under Craniopharyngioma; 19 are open to participants now.
This study's planned enrollment of 608 is above the median of 180 across 21 observational studies indexed under Craniopharyngioma.
Browse Craniopharyngioma studies →This is the only study on the registry with Cheng sen as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Patients diagnosed of tumor in sellar region with unruptured intracranial aneurysms in the Chinese population
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tumor resection followed by aneurysm treatment
Procedure: Tumor resection followed by aneurysm treatment
Aneurysm treatment followed by tumor resection
Procedure: Aneurysm treatment followed by tumor resection
Tumor resection without aneurysm treatment but observation
Other: Observation
Tumor resection followed by aneurysm treatment
Aneurysm treatment followed by tumor resection
Tumor resection without aneurysm treatment but observation
Aneurysm progression
The diameter of aneurysm neck, the diameter of aneurysm dome, the volume of aneurysm, aneurysm rupture status
Time frame: From enrollment to the end of treatment at 24 months
Tumor related complication and progression
The related complication and progression of tumor in sellar region: pituitary hormone level, visual acuity and visual field, hydrocephalus and tumor recurrence.
Time frame: From enrollment to the end of treatment at 24 months
Plan to share: Undecided — The IPD used and/or analyzed during the current study are available from the researcher on reasonable request.
Started Oct 2026 (actual). Primary completion is estimated for Sep 2028, 22 months after the start.
Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Oct 21, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.